Ashish Kamat, MD, MBBS, FACS

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Janssen (+Taris)
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Fergene
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Roche
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Engene
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Ferring
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    TMC Innovation
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Biological Dynamics
    Mitigation strategy: 
    Divest
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Urogen
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Incyte DSMB
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Theralase
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    08/25/2023

Pages

Return to The Journal of Urology Vol. 210 (2023): November